Company News
Company News
Core One in Talks with Multiple Companies to Supply Psilocybin
May 05, 2023
Vancouver, British Columbia, Canada – May 5, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN:...
Read more
Company News
Core One Labs’ GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
May 01, 2023
Vancouver, British Columbia, Canada – May 1, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN:...
Read more
Company News
Core One’s Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
April 21, 2023
Vancouver, British Columbia, Canada – April 21, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs Applauds Study Linking Psychedelic Treatment to Substantial Reduction in Alcohol Misuse & PTSD Symptoms in US Special Operations Forces Veterans
April 04, 2023
Vancouver, British Columbia, Canada – April 4, 2023 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
Core One Labs’ Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
January 24, 2023
Vancouver, British Columbia, Canada – January 24, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more
Company News
Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and other Drug Developers
January 13, 2023
Vancouver, British Columbia, Canada – January 13, 2023 – Core One Labs Inc. (CSE: COOL), (OTCQB: CLABF), (Frankfurt: LD6, WKN: A3CSSU)...
Read more